Insulet Corporation $PODD Shares Sold by SGL Investment Advisors Inc.

Key Points

• SGL Investment Advisors Inc. reduced its holdings in Insulet Corporation by 71.9% in the second quarter, selling a total of 2,024 shares, leaving it with an ownership of 792 shares valued at approximately $235,000.
• Insulet's stock opened at $311.69, having a market capitalization of $21.94 billion, and reported a significant year-over-year revenue increase of 32.9% in its latest quarterly earnings.
• Analysts have raised their target prices for Insulet, with Rothschild & Co increasing theirs from $350.00 to $370.00, reflecting a strong overall sentiment with an average rating of "Moderate Buy".

SGL Investment Advisors Inc. lessened its holdings in Insulet Corporation (NASDAQ:PODD - Free Report) by 71.9% in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 792 shares of the medical instruments supplier's stock after selling 2,024 shares during the period. SGL Investment Advisors Inc.'s holdings in Insulet were worth $235,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently bought and sold shares of PODD. Larson Financial Group LLC raised its stake in Insulet by 426.3% during the 1st quarter. Larson Financial Group LLC now owns 100 shares of the medical instruments supplier's stock worth $26,000 after acquiring an additional 81 shares in the last quarter. Zions Bancorporation National Association UT acquired a new position in Insulet during the first quarter worth approximately $26,000. SouthState Corp lifted its stake in Insulet by 253.3% in the first quarter. SouthState Corp now owns 106 shares of the medical instruments supplier's stock valued at $28,000 after buying an additional 76 shares during the last quarter. Kozak & Associates Inc. acquired a new stake in shares of Insulet in the second quarter valued at approximately $32,000. Finally, Ramirez Asset Management Inc. acquired a new position in shares of Insulet in the 1st quarter valued at $53,000.

Insider Buying and Selling

In other Insulet news, SVP Prem Singh sold 687 shares of Insulet stock in a transaction that occurred on Monday, September 8th. The stock was sold at an average price of $347.49, for a total value of $238,725.63. Following the completion of the transaction, the senior vice president directly owned 3,456 shares in the company, valued at $1,200,925.44. The trade was a 16.58% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, SVP Laetitia Cousin sold 797 shares of the firm's stock in a transaction on Monday, September 8th. The shares were sold at an average price of $348.81, for a total value of $278,001.57. Following the transaction, the senior vice president directly owned 3,890 shares in the company, valued at $1,356,870.90. This trade represents a 17.00% decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.39% of the stock is currently owned by insiders.

Insulet Stock Up 0.8%

Shares of NASDAQ:PODD opened at $311.69 on Tuesday. Insulet Corporation has a 52-week low of $225.37 and a 52-week high of $353.50. The company has a quick ratio of 1.81, a current ratio of 2.26 and a debt-to-equity ratio of 0.64. The company has a market capitalization of $21.94 billion, a price-to-earnings ratio of 94.74, a price-to-earnings-growth ratio of 2.57 and a beta of 1.40. The company has a 50 day moving average of $321.73 and a two-hundred day moving average of $299.30.

Insulet (NASDAQ:PODD - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $1.17 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.92 by $0.25. Insulet had a return on equity of 23.78% and a net margin of 10.01%.The company had revenue of $649.10 million for the quarter, compared to the consensus estimate of $612.31 million. During the same period in the previous year, the business earned $0.55 EPS. Insulet's revenue for the quarter was up 32.9% compared to the same quarter last year. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. As a group, analysts forecast that Insulet Corporation will post 3.92 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts have recently commented on the stock. Rothschild & Co Redburn raised their target price on shares of Insulet from $350.00 to $370.00 and gave the stock a "buy" rating in a research note on Friday. Wells Fargo & Company raised their price target on Insulet from $330.00 to $350.00 and gave the company an "overweight" rating in a report on Friday, August 8th. Piper Sandler upped their price objective on Insulet from $320.00 to $360.00 and gave the stock an "overweight" rating in a report on Tuesday, September 16th. Oppenheimer boosted their target price on shares of Insulet from $324.00 to $365.00 and gave the stock an "outperform" rating in a research report on Monday, September 8th. Finally, Barclays increased their price target on shares of Insulet from $266.00 to $300.00 and gave the company an "equal weight" rating in a report on Thursday, August 21st. Seventeen investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $346.83.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.